Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 13/20 | 0.46 |
| ▸ | KLK1 | P06870 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16305597 | 1.00 | KLKB1 (0.46) | KLKB1KLK1GAARAB9AMME | |
| SCHEMBL16305982 | 0.94 | ITGB1 (0.41) | KLKB1MMEANPEP | |
| SCHEMBL16305600 | 0.94 | KLKB1 (0.40) | KLKB1MMEANPEPACACB | |
| SCHEMBL17834904 | 0.94 | KLKB1 (0.40) | KLKB1MMEANPEPACACB | |
| SCHEMBL16305881 | 0.93 | KLKB1 (0.42) | KLKB1KLK1 | |
| SCHEMBL17834747 | 0.93 | ITGB1 (0.44) | KLKB1 | |
| SCHEMBL16305971 | 0.93 | ITGB1 (0.44) | KLKB1 | |
| SCHEMBL16306216 | 0.93 | KLKB1 (0.39) | KLKB1KLK1MMEANPEP | |
| SCHEMBL16306086 | 0.93 | CA2 (0.40) | KLKB1MMEANPEP | |
| SCHEMBL16305599 | 0.93 | CA2 (0.40) | KLKB1MMEANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10034886-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2018-07-31 | — | — | US | disclosed |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2018-01-25 | — | — | US | disclosed |
| US-9795613-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-10-24 | — | — | US | disclosed |
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2016094729-A1 | GLP-1 RECEPTOR MODULATORS | CELGENE INTERNATIONAL II SARL (CH) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228450-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | KLKB1 2855/4885KLK1 2003/4885GAA 3291/4885 |
| US-20180021346-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | KLKB1 2855/4885KLK1 2003/4885GAA 3291/4885 |
| US-10034886-B2 | GLP-1 receptor modulators | GLP1R, GIPR, GCGR | KLKB1 2865/4885KLK1 1782/4885GAA 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.